A pharmaceutical company targeting unmet clinical needs.

Herantis Pharma was created by a merger of two pharmaceutical companies, Hermo Pharma and Laurantis Pharma.

Pipeline

Overview

Herantis has a product development portfolio focused in areas of unmet clinical need, based on internationally recognized science.

Read More

Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin Trial in Breast Cancer-Associated Lymphedema

Herantis Pharma Announces 12-Month Follow-Up Review from Phase 1 Lymfactin® Trial in Breast Cancer-Associated Lymphedema Herantis Pharma Plc Company release…

Read More

Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders

Decisions of Herantis Pharma Plc’s Annual General Meeting of shareholders Herantis Pharma Plc Company release 11 April 2019 at 5:00…

Read More

Herantis Pharma Announces Expansion of its Phase 2 Study AdeLE in Breast Cancer Associated Lymphedema with Two Centers in Sweden

Herantis Pharma Announces Expansion of its Phase 2 Study AdeLE in Breast Cancer Associated Lymphedema with Two Centers in Sweden…

Read More

Investors

Herantis shares are listed on NASDAQ OMX Helsinki First North Finland. Read More

New therapies for a better life.